Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1067P - Correlation between the number of risk factors and relapse in patients with cutaneous squamous cell carcinoma: A predictive factor for accurate adjuvant radiotherapy?

Date

16 Sep 2021

Session

ePoster Display

Topics

Radiation Oncology

Tumour Site

Basal Cell and Squamous Cell Cancers of the Skin

Presenters

Adeline Petre

Citation

Annals of Oncology (2021) 32 (suppl_5): S867-S905. 10.1016/annonc/annonc706

Authors

A. Petre1, P. Pommier2, S. Chabaud3, T. Brahmi2, S. Darnis4, M. Amini Adle5

Author affiliations

  • 1 Radiotherapy, Centre Léon Bérard, 69008 - Lyon/FR
  • 2 Radiotherapy, Centre Léon Bérard, 69008 - lyon/FR
  • 3 Biostatistics And Therapeutics Evaluation Unit, Centre Léon Bérard, 69373 - Lyon/FR
  • 4 Delegation For Clinical Research And Innovation, Centre Léon Bérard, 69008 - lyon/FR
  • 5 Dermatology, Centre Léon Bérard, 69008 - lyon/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1067P

Background

Despite clinical and histopathological factors are associated with high-risk cutaneous-squamous cell carcinoma (cSCC), equivocal definition for high-risk cSCC patients is lacking and their management remains challenging. We aim to identify factors predicting relapse in cSCC patients treated with surgery, combined or not with radiotherapy (RT) and to assess if adjuvant RT was associated with benefits in PFS.

Methods

This retrospective analysis included patients with resectable cSCC treated with surgery and/or RT in curative intent, at Centre Léon Bérard (Lyon, France) from April 2010 to September 2020. Independent predictive factors for relapse were searched using Cox regression analyses. The benefit of adjuvant RT was assessed according to the number of risk factors. PFS was estimated using the Kaplan-Meier method. Lesions were used as statistical units.

Results

A total of 303 patients with 529 cSCC were included. The median number of lesions per patient was 3 (1-25). With a median follow-up of 54 (0.2-126) months, 103 cSCC relapsed. The multivariate analysis identified as predictive factor for relapse in cSCC treated with exclusive surgery, the number of risk factors (HR 15.110 [3.91-58.40] for ≥3 risk factors, HR 4.497 [1.47-13.76] for 1 risk factor, p<0.001), low differentiation (HR 4.930 [2.47-9.86], p<0.001) and perineural involvement (HR 2.442 [1.11-5.38], p=0.027). Deep invasion, location, and tumour size were not significantly associated with higher risk of relapse. 31 cSCC were treated with surgery and adjuvant RT. Considering cSCC with equal number of risk factors, cSCC treated with surgery and adjuvant RT tended to associate with better PFS than cSCC treated with surgery alone (HR 0.47 [0.20-1.14], p=0.087). In the subgroup of cSCC with ≥3 risk factors, a significantly better PFS is observed in cSCC treated with surgery and adjuvant RT compared with those treated with exclusive treatment (p=0.0283).

Conclusions

Increased number of risk factors identified as a predictive factor of relapse in cSCC. Adjuvant RT improved PFS in cSCC with ≥3 risk factors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.